# Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

> **NCT04688658** · PHASE1,PHASE2 · TERMINATED · sponsor: **John Kirkwood** · enrollment: 13 (actual)

## Conditions studied

- Unresectable Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT04688658
- **Lead sponsor:** John Kirkwood
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-06
- **Primary completion:** 2024-02-22
- **Final completion:** 2025-02-01
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Secura Bio, Inc. discontinued support of the trial.
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688658, "Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04688658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*